MedPath

The effects of probiotic and prebiotic supplementation on Non Alcoholic Fatty Liver Disease

Phase 2
Conditions
on alcoholic fatty liver.
Other diseases of liver
Registration Number
IRCT201410052394N13
Lead Sponsor
Vice-chancellor for research, Iran University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
105
Inclusion Criteria

Willing to participate and signed the consent; Elevated serum levels of liver enzymes( ALT greater than 1.5 times normal); More than one degree of steatosis on ultrasonography in patients; No alcohol abuse (consuming more than 10 grams for women and 20 grams for men) and opium abuse; Body Mass Index equal to or greater than 25 Kg/m2 and equal to or less than 40 Kg/m2; The absence of other acute and chronic diseases and disorders of the liver (hepatitis B, C, ...), cirrhosis, celiac disease, diabetes, hypertension, cardiovascular disease, kidney disease, lung disease; No pregnancy and lactation; Not taking metformin, vitamin E, orso de Oxy-colic acid and weight-loss drugs, hepatotoxic , antibiotics, corticosteroids, NSAIDs and other medications; no history of weight loss surgery in the past year; Failure to lose weight in 3 months; nonsmoking; aged 20-60 years; without the use of supplemental multivitamins, minerals and omega-3 (nutritional supplements); not using the contraceptive pill.
Exclusion criteria:
Taking antibiotics for over a week during the study period; Personal desire to withdraw from the study; Not consume more than 10% of the capsules at any follow up; Any changes in recommended diet and daily physical activity; being pregnant during the intervention.

Exclusion Criteria

Not provided

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath